Active Participants195Unique individuals
Avg Weight Loss (12 Weeks)15.9 kgFrom program start
Most Used PeptideRetatrutideUsed by 72.8% of cohort
Avg Program Duration10.4 weeksAverage total duration
Class Action Linked62%Participants linked
Compound Overview
♧Retatrutide
Usage72.8% (142)Participants142Avg Weekly Dose2.0 mg – 5 mgAvg Duration10.2 weeks
Avg Weight Change (12 Weeks)-16.2 kg
♧Tirzepatide
Usage15.9% (31)Participants31Avg Weekly Dose2.5 mg – 7.5 mgAvg Duration10.3 weeks
Avg Weight Change (12 Weeks)-14.3 kg
♧Semaglutide
Usage8.7% (17)Participants17Avg Weekly Dose1.0 mg – 2.4 mgAvg Duration9.9 weeks
Avg Weight Change (12 Weeks)-12.6 kg
♧Cagrilintide
Usage2.6% (5)Participants5Avg Weekly Dose2.0 mg – 4.0 mgAvg Duration9.2 weeks
Avg Weight Change (12 Weeks)-11.1 kg
Compound Usage Mix
195Total
Retatrutide72.8% (142)
Tirzepatide15.9% (31)
Semaglutide8.7% (17)
Cagrilintide2.6% (5)
Avg Weight Change by Compound (12 Weeks)
RetatrutideTirzepatideSemaglutideCagrilintide
Weekly Weight Change Trend by Compound
RetatrutideTirzepatideSemaglutideCagrilintide
Compound Comparison Table
| Compound | Cohort Size | Dose Range (Weekly) | Avg Duration (Weeks) | Avg Weight Change (12 Weeks) |
|---|---|---|---|---|
| ♧Retatrutide | 142 (72.8%) | 2.0 mg – 5 mg | 10.2 | -16.2 kg |
| ♧Tirzepatide | 31 (15.9%) | 2.5 mg – 7.5 mg | 10.3 | -14.3 kg |
| ♧Semaglutide | 17 (8.7%) | 1.0 mg – 2.4 mg | 9.9 | -12.6 kg |
| ♧Cagrilintide | 5 (2.6%) | 2.0 mg – 4.0 mg | 9.2 | -11.1 kg |
▣ July entrants have not yet completed a full 12-week cycle. Detailed 12-week outcome charts remain anchored to the mature June cohort baseline while July follow-up data accumulates.